NovaBridge Biosciences business relationships

Companies named in NovaBridge Biosciences’s 20-F filed 2026-04-07, and public companies whose annual reports name NovaBridge Biosciences. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 3.5 / 10
AI naming: <1 / 100
Agent readiness: 20 / 100
AI adoption: 0 / 100

Named in NovaBridge Biosciences’s annual report 7

BRISTOL MYERS SQUIBB CO (BMY)Partner7.7
“...June 2024, we entered into a clinical trial collaboration and supply agreement (the "BMS Collaboration Agreement") with Bristol-Myers Squibb Company ("BMS") to evaluate our novel bispecific antibody, givastomig, targeting Claudin18.2 x 4-1BB in clinical trials, in combination with BMS's anti-PD-1 mo...” SEC filing
BRISTOL MYERS SQUIBB CO (BMY)Supplier7.7
“Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb” SEC filing
AbbVie Inc. (ABBV)Partner5.2
“..., and as a result, we have incurred net losses since the commencement of our operations to 2014, with the exception of 2020 during which we generated net income primarily attributable to the revenues recognized in connection with the strategic collaboration with AbbVie, which was terminated in 2023.” SEC filing
ABL Bio Inc.Partner4.9
“The transaction provides us with the rights worldwide, subject to a bispecific collaboration agreement with ABL Bio, Inc., ("ABL Bio"), to bispecific and multi-specific applications, including bispecific and multi-specific antibodies and antibody drug conjugates ("ADCs"), based on the Claudin 18.2 (...” SEC filing
EVEREST GROUP, LTD. (EG)Licensor4.7
“Licensing Agreement with AskGene and Everest” SEC filing
Tracon Pharmaceuticals, Inc.Partner4.7
“Collaboration Agreements with Tracon Pharmaceuticals, Inc.” SEC filing
Visara, Inc.Licensor4.2
“Exclusive License Agreement, dated as of October 15, 2025, by and between AskGene Pharma, Inc. and Visara, Inc. (incorporated by reference to exhibit 1.4 to the Current Report on Form 6-K/A (File No. 001-39173) furnished with the SEC on October 24, 2025)” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.